- Home
- SLI vs PRTA Comparison
SLI vs PRTA Comparison
Compare SLI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLI | PRTA |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.8M | 495.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLI | PRTA |
|---|---|---|
| Price | $4.47 | $9.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $5.25 | ★ $18.86 |
| AVG Volume (30 Days) | ★ 4.0M | 783.4K |
| Earning Date | 11-10-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $819.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $4.32 |
| 52 Week High | $6.40 | $16.67 |
Technical Indicators
Market Signals| Indicator | SLI | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 42.65 |
| Support Level | $4.45 | $9.23 |
| Resistance Level | $5.25 | $9.88 |
| Average True Range (ATR) | 0.28 | 0.43 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 3.14 | 25.17 |
Price Performance
Historical ComparisonAbout SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.